Pharvaris lands another $80M as it looks to tackle Takeda and CSL with an oral approach for HAE

A year after their $66 million launch, the Swiss upstart Pharvaris has managed to convince another fleet of new and returning investors to back their upstart approach for a rare genetic condition called hereditary angioedema, or HAE.